印ワクチン大手CEO、原料の禁輸解除を米大統領に「直訴」
このツイートをしたのはインド血清研究所のアダール・プーナワラ最高経営責任者(CEO)。発展途上国への新型コロナワクチン供給が危機にあることを強調した。
「尊敬する @POTUS(米大統領)、このウイルスを撃退するうえで私たちが本当に結束するのなら、ワクチンの増産が可能になるよう、原料の輸出禁止措置を解除することを、米国外のワクチン業界に代わり、謹んでお願いします」とツイートした。バイデン氏からの返答はまだない。
ワクチン生産量で世界最大のSIIは、英製薬大手アストラゼネカが開発した新型コロナワクチンを製造している。感染拡大の第2波に見舞われたインドが同ワクチンの輸出を制限したことを受け、どうすれば需要を満たせるのか、対応に苦慮している。【翻訳編集AFPBBNews】
〔AFP=時事〕(2021/04/21-13:41)
Vaccine giant tweets Biden to end US raw materials 'embargo'
The head of the world's largest vaccine maker directly tweeted US President Joe Biden on Friday urging him to lift an export ban on raw materials desperately needed to make more coronavirus shots.
The unusual step by Serum Institute (SII) chief Adar Poonawalla underlined the crisis in providing vaccines to developing nations, many of which rely heavily on the firm for supplies.
Respected @POTUS, if we are to truly unite in beating this virus, on behalf of the vaccine industry outside the U.S., I humbly request you to lift the embargo of raw material exports out of the U.S. so that vaccine production can ramp up, he tweeted.
There was no immediate response from the US leader on Twitter.
The world's biggest vaccine producer by volume, SII has struggled to meet demand for the AstraZeneca jab, which it manufactures, after India put the brakes on allowing exports of the shots as it battles a ferocious second wave.
Poonawalla said last week that production was very stressed and called on the Indian government to provide it with financial assistance.
The company's production of a jab developed by US firm Novavax has also hit roadblocks due to the US restrictions, with Poonawalla telling an Indian newspaper last week that the embargo was as good as banning vaccines.
Developed in record time, the dozen or so Covid-19 vaccines already in use around the world have already triggered an exponential increase in production, meaning raw materials are now running short.
SII, which struck a deal to supply 200 million doses to Covax, a World Health Organization-backed effort to procure and distribute inoculations to poor countries, has seen its profile soar since the pandemic, with rich nations also clamouring to buy its jab.
But the Covax programme has been hampered by wealthy nations hogging the supply, with the WHO chief Tedros Adhanom Ghebreyesus on Thursday criticising the shocking and expanding disparity in the global distribution of vaccines.
The company recorded annual revenues of more than $800 million in 2019-20, but the export ban has prompted it to ask India's government for financial help since New Delhi pays it less per shot than it earns from overseas sales.
New Delhi on Friday announced that it would provide financial support to Indian vaccine developer Bharat Biotech, so it could scale up its production of the home-grown Covaxin jab.
The government said it aimed to increase production capacity to nearly 100 million doses a month by September.
India, which has recorded over 14 million infections since the start of the pandemic, began vaccinating people aged over 45 this month, aiming to inoculate 300 million people by August. So far it has administered around 117 million shots.
最新ニュース
-
物価上振れなら利上げ=日銀総裁「無視できない円安」は考慮―政策金利据え置き・決定会合
-
17競技団体「統合検討したい」=スポーツ庁の調査結果
-
円下落、一時156円80銭台=介入警戒感で乱高下―ロンドン市場
-
ANAHD、純利益最高=国際線が好調―24年3月期
-
営業収入、100億円超=J1浦和
写真特集
-
【大相撲】大関・琴ノ若
-
【女子フィギュア】千葉百音
-
【野球】野球殿堂に入った名選手
-
【駅伝】第100回箱根駅伝
-
【女子フィギュア】吉田陽菜
-
【男子フィギュア】山本草太
-
【野球】日本シリーズ関西対決 阪神が38年ぶり日本一
-
【MLB】ドジャースの歴代日本選手